StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Arpit Beriwal, Motilal Oswal

BUYSun Pharmaceutical Industries Ltd.

byArpit Beriwal, Motilal OswalHorizon: 1–3 months30 Jul 2026via ET Now

Entry₹2,016.4Inferred
Target₹2,100
Total upside +4.15%
Stop lossNot given
CMP₹1,840Just now
Active-8.75%+14.13%upside left 7 wk left
Follow Arpit Beriwal for new callsGet alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 3 other Short-term calls on SUNPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 14 Sept, 4:04 pm IST
10 supporting3 neutral4 opposing
Supports the BUY call (10)

MACD above its signal line — bullish momentum

Technicals · macd·14 Sept · today

10 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·2 Sept · 2w ago

Sun Pharma participated in a White House ceremony, announcing agreements with the U.S. government to prioritize access to affordable medicines. The company committed to Most Favored Nation (MFN) prici

BSE · Company Update·1 Sept · 2w ago

(opens in new tab)

Sun Pharma and its subsidiaries have won an antitrust litigation in the US related to the Lipitor patent settlement. The US Court of Appeals affirmed a summary judgment in their favor, denying class c

BSE · Company Update·17 Aug · 4w ago

(opens in new tab)

3 other SEBI-registered advisors have active short-term BUY calls on this stock

Advisor consensus · same horizon·30 Jul · 2mo ago

Neutral / worth noting (3)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 5d ago

(opens in new tab)
Weighs against the BUY call (4)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 2d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.